For years, the Medicare prescription drug benefit Part D has been credited with positively impacting national trends in health outcomes and medical services. But a recent study challenges that assumption and suggests that the U.S. Congressional Budget Office's adopted a new costing method based on assumed cost-savings may be "premature."
No comments:
Post a Comment